AB Science SA
PAR:AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AB Science SA
PAR:AB
|
FR |
|
Future Data Group Ltd
HKEX:8229
|
KR |
|
Dmg Blockchain Solutions Inc
XTSX:DMGI
|
CA |
|
T
|
Tanger Inc
SWB:T6O
|
US |
|
Mohit Industries Ltd
NSE:MOHITIND
|
IN |
|
I
|
International Gas Product Shipping JSC
VN:GSP
|
VN |
|
Fairwood Holdings Ltd
HKEX:52
|
HK |
|
Otokar Otomotiv ve Savunma Sanayi AS
IST:OTKAR.E
|
TR |
|
Eagle Industry Co Ltd
TSE:6486
|
JP |
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
KR |
|
L
|
Lennar Corp
NYSE:LEN.B
|
US |
|
Mach7 Technologies Ltd
ASX:M7T
|
AU |
|
I
|
Insolation Energy Ltd
BSE:543620
|
IN |
|
Novorossiyskiy Morskoy Torgovyi Port PAO
MOEX:NMTP
|
RU |
|
N
|
Nation International Edutainment PCL
SET:NINE
|
TH |
|
B
|
Believe SA
PAR:BLV
|
FR |
|
Svolder AB
STO:SVOL A
|
SE |
|
Post Holdings Inc
NYSE:POST
|
US |
|
M
|
MyTech Group Bhd
KLSE:MYTECH
|
MY |
|
IDE Group Holdings PLC
LSE:IDE
|
UK |
|
C
|
Cryo-Cell International Inc
AMEX:CCEL
|
US |
|
KIYO Learning Co Ltd
TSE:7353
|
JP |
|
C
|
Cresud SACIF y A
BCBA:CRES
|
AR |
|
R
|
Robotis Co Ltd
KOSDAQ:108490
|
KR |
AB Science SA
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
